Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Antigenics Oncophage

Executive Summary

Antigenics expects Oncophage (HSPPC-96) Phase III melanoma trial enrollment to be completed by the end of 2004 after FDA lifts partial clinical hold on cancer vaccine. FDA requested additional data on "product characterization issues" (1"The Pink Sheet" Sept. 8, 2003, p. 28). Enrollment for the kidney trial is almost complete...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS042901

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel